Company Creates New Glow Type Luciferase Detection Reagent and is Offering it as an Easy-To-Use Kit State College, PA (18 January 2022) – INDIGO Biosciences, Inc. (INDIGO), a recognized industry leader in cell-based luciferase reporter assay kits and service, has developed a new luciferase detection reagent and will be offering this new reagent solely forRead More
INDIGO Biosciences Expands Portfolio for Preclinical Metabolic Disease Research
Fibroblast Growth Factor 21 Assay Targets NAFLD & Obesity State College, PA (19 October 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, after the success of their Fibroblast Growth Factor Receptor 1 and 2 (FGFR1/2) assay, has expanded their robust preclinical testing portfolio to include a new Fibroblast Growth Factor 1c/BetaRead More
INDIGO Biosciences Expands Portfolio for Preclinical Development and Oncology Research
Fibroblast Growth Factor Receptor 1&2 Assay Targets Cell Growth & Tumor Progression State College, PA (31 August 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust preclinical testing portfolio to include a new Fibroblast Growth Factor Receptor 1&2 (FGFR1/2) assay primarily implicated in diabetes, kidney disease, and theRead More
INDIGO Biosciences Announces Addition of TPOR Assay to Pre-Clinical Portfolio
Thrombopoietin Receptor Indicated in Anemia & Blood Cancer Treatment Development State College, PA (10 August 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded its pre-clinical portfolio to include the Thrombopoietin Receptor (TPOR). Responsible for platelet production, TPOR is primarily used in developing treatments related to familial aplastic anemia andRead More